Drugs / SumayaVac-1
last change Apr 2024 re-read 2 minutes ago

SumayaVac-1

also known as SUM-101

Vaccine

Developed for
malaria
Investigated by
Ifakara Health Institute · Sumaya Biotech GmbH & Co. KG · Swiss Tropical & Public Health Institute

Trials 1 · a red edge is where a trial was stopped

202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05644067 Aug 2023 → Apr 2024 malaria Swiss Tropical & Public Health Institute Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SumayaVac-1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05644067
Known as SUM-101 “candidate malaria vaccine, SumayaVac-1 (SUM-101)” NCT05644067
Modality Vaccine “candidate dual-stage malaria vaccineNCT05644067
Route Intramuscular “Vaccination: Intra-muscular injection of SumayaVac-1 (SUM-101)” NCT05644067